Roche silences Herceptin comparison

Share this article:

Biosimilar Herceptin is coming to India, but marketers will not be able to say so. The Wall Street Journal reported Friday that drugmaker Roche won a case that prevents the biosimilar manufacturer from using the brand name Herceptin in its marketing.

The decision also bars Biocon-Mylan from making comparisons between its lookalike breast cancer treatment's manufacturing processes, safety, efficacy and sales, with those of Herceptin.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.